Who Supplies Empagliflozin to India from CANADA

To import finished pharmaceutical formulations containing Empagliflozin into India, the following regulatory approvals are mandatory:

1. Import License: An Importer Exporter Code (IEC) from the Directorate General of Foreign Trade (DGFT) is required. Additionally, an import license from the Central Drugs Standard Control Organization (CDSCO) is necessary for each consignment.

2. CDSCO Registration: The product must be registered with CDSCO, which involves submitting Form 40 or 41, depending on the product type. This registration ensures the product meets India's safety, efficacy, and quality standards.

3. Drug Controller General of India (DCGI) Approval: The DCGI evaluates the product's clinical data and approves its use in India.

4. No Objection Certificate (NOC): If the product is already marketed in another country, an NOC from the regulatory authority of that country may be required.

The registration process typically takes 6 to 12 months, depending on the product's complexity and the completeness of the submitted documentation.

Imported pharmaceutical formulations containing Empagliflozin must undergo stringent quality control measures:

1. CDSCO-Approved Laboratory Testing: Each batch must be tested in a laboratory approved by CDSCO to ensure compliance with Indian Pharmacopoeia standards.

2. Certificate of Analysis (CoA): A CoA from the manufacturer, detailing the product's composition, potency, and purity, is required for each batch.

3. Stability Data: Stability studies must be conducted under ICH Zone IV conditions to demonstrate the product's shelf-life in India's climate.

4. Port Inspection: Upon arrival, customs drug inspectors may perform random sampling and testing to verify compliance with Indian standards.

Failure to meet these requirements can result in delays, rejections, or destruction of the consignment.

Between 2024 and 2026, India has implemented several regulatory updates affecting pharmaceutical imports:

1. Mandatory Import Registration and License: As of April 2025, the CDSCO has mandated that all imported drugs, including finished formulations, must obtain import registration and licenses as per the Drugs and Cosmetics Act and Rules.

2. Pharmaceuticals PLI Scheme Impact: The Production Linked Incentive (PLI) scheme, introduced to boost domestic manufacturing, may influence the import of certain pharmaceutical products, including Empagliflozin formulations.

3. Bilateral Agreements with Canada: Ongoing discussions aim to streamline regulatory processes and enhance trade relations between India and Canada, potentially affecting pharmaceutical imports.

These changes aim to enhance drug safety, promote domestic manufacturing, and strengthen bilateral trade ties.

India imports finished Empagliflozin formulations to meet the growing demand for diabetes management:

1. Patented Formulations: Certain patented Empagliflozin formulations not available domestically are imported to provide patients with the latest treatment options.

2. Specific Dosage Forms: Specialized dosage forms, such as combination tablets, are imported to cater to diverse patient needs.

3. Domestic Capacity vs. Import Dependency: While India has a robust pharmaceutical manufacturing sector, the complexity and cost of producing certain formulations lead to reliance on imports.

4. Market Size: The Indian market for Empagliflozin formulations is substantial, with imports supplementing domestic production to meet patient needs.

This import strategy ensures access to a comprehensive range of treatment options for diabetes patients in India.

The import of finished pharmaceutical formulations containing Empagliflozin is subject to the following duties and taxes:

1. Basic Customs Duty (BCD): A standard rate of 10% is applied to the CIF (Cost, Insurance, and Freight) value.

2. Social Welfare Surcharge (SWS): Calculated at 10% of the BCD, amounting to 1% of the CIF value.

3. Integrated Goods and Services Tax (IGST): Levied at 12% on the total of CIF value, BCD, and SWS.

4. Total Landed Duty: Approximately 23.536% of the CIF value, considering abatement factors.

These duties are subject to change based on government notifications and trade agreements.

India sources finished Empagliflozin formulations from Canada due to several competitive advantages:

1. Patents and Specialized Dosage Forms: Canadian manufacturers offer patented formulations and specialized dosage forms not available domestically.

2. Quality Assurance: Canada's stringent regulatory standards ensure high-quality products, instilling confidence among Indian importers.

3. Regulatory Compliance: Canadian pharmaceutical companies adhere to international standards, facilitating smoother import processes.

While other countries like China, Germany, and the US also supply Empagliflozin formulations, Canada's unique combination of quality, innovation, and regulatory compliance makes it a preferred source for India.